Open Access

MicroRNA‑9 enhances chemotherapy sensitivity of glioma to TMZ by suppressing TOPO II via the NF‑κB signaling pathway

  • Authors:
    • Qingla Li
    • Yingnan Chang
    • Luyan Mu
    • Yuwen Song
  • View Affiliations

  • Published online on: March 18, 2019     https://doi.org/10.3892/ol.2019.10158
  • Pages: 4819-4826
  • Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Glioma is the most common primary tumor of the central nervous system (CNS) that develops chemotherapy resistance. The microRNA (miRNA) miR‑9 is a tissue‑specific miRNA of the CNS that may serve a key role in the modulation of chemotherapy sensitivity. The aim of the present study was to investigate the effect of miR‑9 on glioma chemotherapy sensitivity by altering the expression of miR‑9 in U251 glioma cells by viral transfection and subsequently treating with gradient concentrations of temozolomide (TMZ). Cell viability, apoptosis and the cell cycle were examined, and drug resistance genes were analyzed by western blotting. The role of nuclear factor κB (NF‑κB) in this regulation was also examined. The results revealed that the susceptibility of glioma cells to TMZ was enhanced by miR‑9 overexpression. When miR‑9 and TMZ were applied together, the apoptotic rate and percentage of cells arrested at the G2/M stage were significantly higher compared with either treatment alone. Topoisomerase II expression was suppressed by miR‑9 via the NF‑κB signaling pathway, which may be responsible for the sensitization. The results of the present study suggested that miR‑9 may be a potential target for glioma chemotherapy.

References

1 

Komori T: The 2016 WHO Classification of tumors of central nervous system: The major point of revision. Neurol Med Chir. 57:301–311. 2017. View Article : Google Scholar

2 

Chung AS, Wu X, Zhuang G, Ngu H, Kasman I, Zhang J, Vernes JM, Jiang Z, Meng YG, Peale FV, et al: An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med. 19:1114–1123. 2013. View Article : Google Scholar : PubMed/NCBI

3 

Zhao Y, Xue Y, Zhang Q, Wang K, Yin J and Lou M: Transcriptional expression of glioma chemotherapy drugs associated marker molecules in gliomas and normal brain tissues. Cancer Biomark. 13:59–66. 2013. View Article : Google Scholar : PubMed/NCBI

4 

Hermisson M, Klumpp A, Wick W, Wischhusen J, Nagel G, Roos W, Kaina B and Weller M: O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem. 96:766–776. 2006. View Article : Google Scholar : PubMed/NCBI

5 

Roos WP, Batista LF, Naumann SC, Wick W, Weller M, Menck CF and Kaina B: Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene. 26:186–197. 2007. View Article : Google Scholar : PubMed/NCBI

6 

Iorio MV and Croce CM: MicroRNAs in cancer: Small molecules with a huge impact. J Clin Oncol. 27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI

7 

Omura N, Li CP, Li A, Hong SM, Walter K, Jimeno A, Hidalgo M and Goggins M: Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma. Cancer Biol Ther. 7:1146–1156. 2008. View Article : Google Scholar : PubMed/NCBI

8 

Hildebrandt MA, Gu J, Lin J, Ye Y, Tan W, Tamboli P, Wood CG and Wu X: Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma. Oncogene. 29:5724–5728. 2010. View Article : Google Scholar : PubMed/NCBI

9 

Song Y, Mu L, Han X, Li Q, Dong B, Li H and Liu X: MicroRNA-9 inhibits vasculogenic mimicry of glioma cell lines by suppressing Stathmin expression. J Neurooncol. 115:381–390. 2013. View Article : Google Scholar : PubMed/NCBI

10 

Song Y, Mu L, Han X, Liu X and Fu S: siRNA targeting stathmin inhibits invasion and enhances chemotherapy sensitivity of stem cells derived from glioma cell lines. Acta Biochim Biophys Sin (Shanghai). 46:1034–1040. 2014. View Article : Google Scholar : PubMed/NCBI

11 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

12 

Krichevsky AM, Sonntag KC, Isacson O and Kosik KS: Specific microRNAs modulate embryonic stem cell-derived neurogenesis. Stem Cells. 24:857–864. 2006. View Article : Google Scholar : PubMed/NCBI

13 

Shibata M, Kurokawa D, Nakao H, Ohmura T and Aizawa S: MicroRNA-9 modulates cajal-retzius cell differentiation by suppressing Foxg1 expression in mouse medial pallium. J Neurosci. 41:10415–10421. 2008. View Article : Google Scholar

14 

Otaegi G, Pollock A, Hong J and Sun T: MicroRNA miR-9 modifies motor neuron columns by a tuning regulation of FoxP1 levels in developing spinal cords. J Neurosci. 31:809–818. 2011. View Article : Google Scholar : PubMed/NCBI

15 

Bonev B, Pisco A and Papalopulu N: MicroRNA-9 reveals regional diversity of neural progenitors along the anterior-posterior axis. Dev Cell. 20:19–32. 2011. View Article : Google Scholar : PubMed/NCBI

16 

Wang J, Gu Z, Ni P, Qiao Y, Chen C, Liu X, Lin J, Chen N and Fan Q: NF-kappaB P50/P65 hetero-dimer mediates differential regulation of CD166/ALCAM expression via interaction with micoRNA-9 after serum deprivation, providing evidence for a novel negative auto-regulatory loop. Nucleic Acids Res. 39:6440–6455. 2011. View Article : Google Scholar : PubMed/NCBI

17 

Myatt S, Wang J, Monteiro L, Christian M, Ho KK, Fusi L, Dina RE, Brosens JJ, Chaem-Maghami S and Lam EW: Definition of microRNAs that repression expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res. 70:367–377. 2010. View Article : Google Scholar : PubMed/NCBI

18 

Wan H, Guo L, Liu T, Liu M, Liu X and Tang H: Regulation of the transcription factor NF-κB1 by microRNA-9 in human gastric adenocarcinoma. Mole Cancer. 9:162010. View Article : Google Scholar

19 

Laios A, O'Toole S, Flavin R, Martin C, Kelly L, Ring M, Finn SP, Barrett C, Loda M, Gleeson N, et al: Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mole Cancer. 7:352008. View Article : Google Scholar

20 

Nass D, Rosenwald S, Meiri E, Gilad S, Tabibian-Keissar H, Schlosberg A, Kuker H, Sion-Vardy N, Tobar A, Kharenko O, et al: MiR-92b and miR-9/9* are specifically expressed in brain primary tumors and can be used to differentiate primary from metastatic brain tumors. Brain Pathol. 19:375–383. 2009. View Article : Google Scholar : PubMed/NCBI

21 

Schraivogel D, Weimann L, Beier D, Tabatabai G, Eichner A, Zhu JY, Anton M, Sixt M, Weller M, Beier CP, et al: CAMTA1 is a novel tumour suppressor regulated by miR-9/9* in glioblastoma stem cells. EMBOJ. 30:4309–4322. 2011. View Article : Google Scholar

22 

Ben-Hamo R and Efroni S: Gene expression and network-based analysis reveals a novel role for hsa-miR-9 and drug control over the p38 network in glioblastoma multiforme progression. Genome Med. 3:772011. View Article : Google Scholar : PubMed/NCBI

23 

Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT and Brock C: Temozolomide: A review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev. 23:35–61. 1997. View Article : Google Scholar : PubMed/NCBI

24 

Nitiss JL: Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer. 9:338–350. 2009. View Article : Google Scholar : PubMed/NCBI

25 

Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, Fiocco R, Foroni C, Dimeco F and Vescovi A: Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 64:7011–7021. 2004. View Article : Google Scholar : PubMed/NCBI

26 

Hong Y, Sang M, Shang C, Xue YX and Liu YH: Quantitative analysis of topoisomerase II alpha and evaluation of its effects on cell proliferation and apoptosis in glioblastoma cancer stem cells. Neurosci Lett. 518:138–143. 2012. View Article : Google Scholar : PubMed/NCBI

27 

Arivazhagan A, Kumar DM, Sagar V, Patric IR, Sridevi S, Thota B, Srividya MR, Prasanna K, Thennarasu K, Mondal N, et al: Higher topoisomerase 2 alpha gene transcript levels predict better prognosis in GBM patients receiving temozolomide chemotherapy: Identification of temozolomide as a TOP2A inhibitor. J Neurooncol. 107:289–297. 2012. View Article : Google Scholar : PubMed/NCBI

28 

Qi XC, Xie DJ, Yang QF, Wang YR, Zhu YX, Qian C and Yang SX: LRG1 dictates the chemo-sensitivity of temzolomide in U251 glioblastoma cells via downregulation of EGFR/topoisomerase-2/bcl-2. Biochem Biophys Res Commun. 437:565–572. 2013. View Article : Google Scholar : PubMed/NCBI

29 

Wong HY, Tsai KD, Liu YH, Yang SM, Chen TW, Cherng J, Chou KS, Chang CM, Yao BT and Cherng JM: Cinnamomum verum component 2-Methoxycinnamaldehyde: A novel anticancer agent with both anti-topoisomerase I and II activities in human lung adenocarcinoma A549 cells in vitro and in vivo. Phytother Res. 30:331–340. 2016. View Article : Google Scholar : PubMed/NCBI

30 

Boland MP, Fitzgerald KA and O'Neill LA: Topoisomerase II required for mitoxantrone to signal nuclear factor κB activation in HL60 cells. J Biol Chem. 275:25231–25238. 2000. View Article : Google Scholar : PubMed/NCBI

31 

Wang Q, Wang Z, Chu L, Li X, Kan P, Xin X, Zhu Y and Yang P: The effects and molecular mechanisms of MiR-106a in multidrug resistance reversal in human glioma U87/DDP and U251/G cell lines. PLoS One. 10:e01254732015. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 17 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Li, Q., Chang, Y., Mu, L., & Song, Y. (2019). MicroRNA‑9 enhances chemotherapy sensitivity of glioma to TMZ by suppressing TOPO II via the NF‑κB signaling pathway. Oncology Letters, 17, 4819-4826. https://doi.org/10.3892/ol.2019.10158
MLA
Li, Q., Chang, Y., Mu, L., Song, Y."MicroRNA‑9 enhances chemotherapy sensitivity of glioma to TMZ by suppressing TOPO II via the NF‑κB signaling pathway". Oncology Letters 17.6 (2019): 4819-4826.
Chicago
Li, Q., Chang, Y., Mu, L., Song, Y."MicroRNA‑9 enhances chemotherapy sensitivity of glioma to TMZ by suppressing TOPO II via the NF‑κB signaling pathway". Oncology Letters 17, no. 6 (2019): 4819-4826. https://doi.org/10.3892/ol.2019.10158